plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.
Although preclinical studies showed promise for difluoromethylornithine
(DFMO) (a competitive inhibitor of ODC) in the setting of BC, this has not been translated into positive results in human subjects.
DFMO, or difluoromethylornithine
, inhibits the synthesis of polyamines, basic compounds in cells.
professor of medicine and biological chemistry at the University of California, Irvine, presented late-breaking results from a phase III trial of difluoromethylornithine
(DFMO), a synthetic inhibitor of ornithine decarboxylase, and sulindac (Clinoril), an NSAID, in 375 patients.
, an effective new treatment of Gambian trypanosomiasis.